cysteamine has been researched along with mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avenoso, A; Calatroni, A; Campo, GM; Campo, S; D'Ascola, A; Micali, A; Nastasi, G; Pisani, A; Puzzolo, D; Scuruchi, M | 1 |
1 other study(ies) available for cysteamine and mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin
| Article | Year |
|---|---|
The SOD mimic MnTM-2-PyP(5+) reduces hyaluronan degradation-induced inflammation in mouse articular chondrocytes stimulated with Fe (II) plus ascorbate.
Topics: Animals; Ascorbic Acid; Cartilage, Articular; Chondrocytes; Cysteamine; Gene Expression Regulation; Hyaluronan Receptors; Hyaluronic Acid; Inflammation; Interleukin-1beta; Iron; Lipid Peroxidation; Male; Matrix Metalloproteinase 13; Metalloporphyrins; Mice; Molecular Weight; NF-kappa B; Nitric Oxide Synthase Type II; Oxidation-Reduction; Peptides; Reactive Oxygen Species; RNA, Messenger; Superoxide Dismutase; Toll-Like Receptor 2; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2013 |